Consensus Incyte Corporation

Equities

INCY

US45337C1027

Real-time Estimate Cboe BZX Other stock markets 12:41:16 2024-06-03 pm EDT			5-day change	1st Jan Change
58.68 ^USD	+1.55%		+2.66%	-6.40%

May. 23	Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	MT
May. 21	Incyte Acquires 2 Office Buildings in Delaware	MT

Evolution of the average Target Price on Incyte Corporation

Price target over the last 5 years

History of analyst recommendation changes

b406f12fa4e2b6be86efe192954fd3c3._x35LEARxm1nAU9FhAhWOKmj-xpN66hmV36XFG296_0.ple-WCFV9QcsMD4ywUFiXsjwzV84tMciZQr2JDvlnoXGW6pVKWKiNDVCDg~3fd73209943f78e01a88279d6c3d2f92

Analyst Recommendations on Incyte Corporation

Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	May. 23	MT
TD Cowen Adjusts Price Target on Incyte to $80 From $88	May. 01	MT
RBC Capital Adjusts Price Target on Incyte to $60 From $65	May. 01	MT
Piper Sandler Adjusts Price Target on Incyte to $80 From $85	May. 01	MT
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63	May. 01	MT
Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating	May. 01	MT
Citigroup Adjusts Price Target on Incyte to $80 From $81	May. 01	MT
BMO Capital Adjusts Incyte Price Target to $52 From $56	May. 01	MT
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained	Apr. 30	MT
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	Apr. 24	MT
BMO Capital Adjusts Price Target on Incyte to $56 From $64	Apr. 19	MT
Jefferies Initiates Incyte With Buy Rating, Price Target is $81	Feb. 23	MT
BMO Capital Adjusts Price Target on Incyte to $64 From $58, Keeps Market Perform Rating	Feb. 14	MT
Citigroup Adjusts Price Target on Incyte to $81 From $82, Keeps Buy Rating	Feb. 14	MT
JMP Securities Downgrades Incyte to Market Perform From Market Outperform	Feb. 14	MT
Truist Securities Adjusts Price Target on Incyte to $84 From $91, Maintains Buy Rating	Feb. 14	MT
Stifel Adjusts Price Target on Incyte to $68 From $67, Maintains Hold Rating	Feb. 14	MT
The market faces a choice	Feb. 14
RBC Lifts PT on Incyte to $65 From $63 on Model Updates Reflecting Monjuvi Integration, Slightly Improved Jakafi/Opzelura Sales Expectations; Sector Perform Kept	Feb. 14	MT
ANALYST RECOMMENDATIONS : Biogen, Gsk, Hp Inc, Palantir, Walt Disney...	Feb. 14
Mizuho Adjusts Incyte's Price Target to $77 From $82, Keeps Neutral Rating	Dec. 14	MT
Leerink Partners Upgrades Incyte to Outperform From Market Perform, Raises Price Target to $78 From $63	Dec. 13	MT
Guggenheim Upgrades Incyte to Buy From Neutral, Price Target is $86	Dec. 04	MT
Goldman Sachs Downgrades Incyte to Neutral From Buy, Cuts Price Target to $65 From $98	Nov. 21	MT
Goldman Sachs Adjusts Price Target on Incyte to $98 From $114, Keeps Buy Rating	Nov. 02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.79 USD

Average target price

72.8 USD

Spread / Average Target

+25.97%

High Price Target

88 USD

Spread / Highest target

+52.28%

Low Price Target

52 USD

Spread / Lowest Target

-10.02%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Incyte Corporation

Deutsche Bank Securities
TD Cowen
RBC Capital Markets
Piper Sandler
Goldman Sachs
Leerink Partners
Citigroup
BMO Capital
Truist Securities
Oppenheimer
Jefferies & Co.
JMP Securities
Stifel Nicolaus
Mizuho Securities
SVB Securities LLC
Guggenheim
Morgan Stanley
BofA Securities
Morningstar
Cowen
Evercore ISI
Wells Fargo Securities
JPMorgan Chase
SVB Leerink
Benchmark Capital
Credit Suisse

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar